Jean George - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Role: Director
Signature: By: /s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 17 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 17 Jun 2021, 21:31:39 UTC
Previous filing: 14 Jun 2021
Next filing: 24 Jun 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CYT	Series B Convertible Preferred Stock							17 Jun 2021	Common Stock	2,200,184		See Footnote	F1, F3
holding	CYT	Series C Convertible Preferred Stock							17 Jun 2021	Common Stock	244,081		See Footnote	F2, F3
holding	CYT	Stock Option (Right to Buy)							17 Jun 2021	Common Stock	17,250	$18.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series B Convertible Preferred Stock are convertible into the number of shares of the Issuer's common stock shown in column 3 and have no expiration date. The Series B Convertible Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F2	The shares of Series C Convertible Preferred Stock are convertible into the number of shares of the Issuer's common stock shown in column 3 and have no expiration date. The Series C Convertible Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F3	Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person, is a managing director of LSV Associates II, LLC. The reporting person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.
F4	The option will vest in full on the earlier of (a) June 17, 2022 and (b) the next annual meeting of stockholders that follows June 17, 2021, in each case subject to the Reporting Person's continued service on the Issuer's board of directors through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney